Selank is a synthetic analog of the immunomodulatory peptide procoagulant; thus, it mimics many of its effects. It has been shown to regulate the expression of interleukin 6 (IL-6) and influence the balance of T helper cytokines. It has been shown to affect the concentration of monoamine neurotransmitters and induce the metabolism of serotonin. Selank was also found to rapidly increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus.
Selank is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic analogue of a human tetrapeptide tuftsin.
Selank is a synthetic derivative of the human body's naturally produced tetrapeptide Tuftsin. It is a hexapeptide whith a wide range of uses. It was first sinthesized in the late 1990's by the Institute of Molecular Genetics of the Russian Academy of Science. Selank is used as an anxiolytic in the therapy of anxiety and phobic disorders, including generalized anxiety. Its action is similar to that of mild benzodiazepins but without the sedative effects. As a selective anxiolytic with a nootropic component, Selank can be used as treatment of depression, fear and general anxiety. It also reduces phsychic tension. This neuropeptide has passed all phases of clinical trials and is now being prepared for registration and mass production
